Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


23.04.2018

4 Ann Surg Oncol
4 BMC Cancer
6 Breast Cancer Res
2 Breast Cancer Res Treat
3 Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Clin Breast Cancer
1 Clin Cancer Res
3 Curr Treat Options Oncol
3 Eur J Cancer
3 Eur J Surg Oncol
3 Int J Cancer
1 Int J Radiat Oncol Biol Phys
5 J Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
1 Oncol Rep
1 PLoS One
4 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. RAUCH GM, Kuerer HM, Adrada B, Santiago L, et al
    Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.
    Ann Surg Oncol. 2018 Apr 17. pii: 10.1245/s10434-018-6481.
    PubMed     Text format     Abstract available

  2. PARK KU, Chen Y, Chitale D, Choi S, et al
    Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2018 Apr 20. pii: 10.1245/s10434-018-6440.
    PubMed     Text format     Abstract available

  3. DUNHAM AL, Ramirez LD, Vang CA, Linebarger JH, et al
    Profiling Surgeon Performance for Breast Cancer Lumpectomy by Composite Measurement of Reoperations, Cosmetic Outcomes, and Patient Preferences.
    Ann Surg Oncol. 2018 Apr 18. pii: 10.1245/s10434-018-6479.
    PubMed     Text format     Abstract available

  4. GIULIANO AE, Edge SB, Hortobagyi GN
    Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.
    Ann Surg Oncol. 2018 Apr 18. pii: 10.1245/s10434-018-6486.
    PubMed     Text format    


    BMC Cancer

  5. LIUTKAUSKIENE S, Grizas S, Jureniene K, Suipyte J, et al
    Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    BMC Cancer. 2018;18:453.
    PubMed     Text format     Abstract available

  6. SEMMLINGER A, von Schoenfeldt V, Wolf V, Meuter A, et al
    EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
    BMC Cancer. 2018;18:431.
    PubMed     Text format     Abstract available

  7. PODRALSKA M, Ziolkowska-Suchanek I, Zurawek M, Dzikiewicz-Krawczyk A, et al
    Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
    BMC Cancer. 2018;18:452.
    PubMed     Text format     Abstract available

  8. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  9. LIU WS, Chan SH, Chang HT, Li GC, et al
    Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.
    Breast Cancer Res. 2018;20:25.
    PubMed     Text format     Abstract available

  10. WEISS A, Bashour SI, Hess K, Thompson AM, et al
    Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Breast Cancer Res. 2018;20:27.
    PubMed     Text format     Abstract available

  11. CHEN J, Wu X, Christos PJ, Formenti S, et al
    Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Breast Cancer Res. 2018;20:26.
    PubMed     Text format     Abstract available

  12. CAMPA D, Barrdahl M, Santoro A, Severi G, et al
    Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
    Breast Cancer Res. 2018;20:29.
    PubMed     Text format     Abstract available

  13. GOORTS B, Dreuning KMA, Houwers JB, Kooreman LFS, et al
    MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
    Breast Cancer Res. 2018;20:34.
    PubMed     Text format     Abstract available

  14. HOUGHTON LC, Knight JA, De Souza MJ, Goldberg M, et al
    Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer.
    Breast Cancer Res. 2018;20:33.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  15. O'SHAUGHNESSY J, DeMichele A, Ma CX, Richards P, et al
    A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast Cancer Res Treat. 2018 Apr 19. pii: 10.1007/s10549-018-4770.
    PubMed     Text format     Abstract available

  16. KROENKE CH, Hershman DL, Gomez SL, Adams SR, et al
    Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Breast Cancer Res Treat. 2018 Apr 18. pii: 10.1007/s10549-018-4774.
    PubMed     Text format     Abstract available


    Cancer

  17. TURK AA, Wisinski KB
    PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31307.
    PubMed     Text format     Abstract available

  18. HIRTH JM, Hatch SS, Lin YL, Giordano SH, et al
    Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31393.
    PubMed     Text format     Abstract available

  19. SHUMWAY DA, Griffith KA, Hawley ST, Wallner LP, et al
    Patient views and correlates of radiotherapy omission in a population-based sample of older women with favorable-prognosis breast cancer.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31378.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  20. WANG S, Ogundiran TO, Ademola A, Oluwasola OA, et al
    Development of a Breast Cancer Risk Prediction Model for Women in Nigeria.
    Cancer Epidemiol Biomarkers Prev. 2018 Apr 20. pii: 1055-9965.EPI-17-1128.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  21. MATTHIESSEN LW, Keshtgar M, Curatolo P, Kunte C, et al
    Electrochemotherapy for Breast Cancer-Results From the INSPECT Database.
    Clin Breast Cancer. 2018 Mar 14. pii: S1526-8209(17)30397.
    PubMed     Text format     Abstract available

  22. YARDLEY DA, Hart LL, Ward PJ, Wright GL, et al
    Cabazitaxel Plus Lapatinib as Therapy for HER2(+) Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.
    Clin Breast Cancer. 2018 Mar 8. pii: S1526-8209(17)30668.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  23. POST AEM, Smid M, Nagelkerke A, Martens JWM, et al
    Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-2551.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  24. SHARMA P
    Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Curr Treat Options Oncol. 2018;19:22.
    PubMed     Text format     Abstract available

  25. REINERT T, Goncalves R, Bines J
    Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
    Curr Treat Options Oncol. 2018;19:24.
    PubMed     Text format     Abstract available

  26. REINERT T, Goncalves R, Ellis MJ
    Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.
    Curr Treat Options Oncol. 2018;19:23.
    PubMed     Text format     Abstract available


    Eur J Cancer

  27. NABIEVA N, Fehm T, Haberle L, de Waal J, et al
    Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
    Eur J Cancer. 2018;96:82-90.
    PubMed     Text format     Abstract available

  28. GOBBINI E, Ezzalfani M, Dieras V, Bachelot T, et al
    Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Eur J Cancer. 2018;96:17-24.
    PubMed     Text format     Abstract available

  29. MAKAMA M, Drukker CA, Rutgers EJT, Slaets L, et al
    Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint((R)))" [Eur J Cancer 75 (April 2017) 5-13].
    Eur J Cancer. 2018 Apr 12. pii: S0959-8049(18)30747.
    PubMed     Text format    


    Eur J Surg Oncol

  30. RUBIO IT
    Variations in the opinion of breast surgeons and radiation oncologist regarding indications for radiation therapy after NSM: The need for prospective studies.
    Eur J Surg Oncol. 2018;44:3-4.
    PubMed     Text format    

  31. LAGENDIJK M, van Egdom LSE, Richel C, van Leeuwen N, et al
    Patient reported outcome measures in breast cancer patients.
    Eur J Surg Oncol. 2018 Mar 21. pii: S0748-7983(18)30954.
    PubMed     Text format     Abstract available

  32. RECHT A
    Postmastectomy radiation therapy: What factors are important in recommending treatment to patients undergoing "Sparing" mastectomies.
    Eur J Surg Oncol. 2018;44:1-2.
    PubMed     Text format    


    Int J Cancer

  33. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
    Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
    PubMed     Text format     Abstract available

  34. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
    Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
    PubMed     Text format     Abstract available

  35. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
    A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  36. TYLER S, Truong PT, Lesperance M, Nichol A, et al
    Close Margins Less Than 2 mm Are Not Associated With Higher Risks of 10-Year Local Recurrence and Breast Cancer Mortality Compared With Negative Margins in Women Treated With Breast-Conserving Therapy.
    Int J Radiat Oncol Biol Phys. 2018 Mar 13. pii: S0360-3016(18)30497.
    PubMed     Text format     Abstract available


    J Clin Oncol

  37. DEGNIM AC, Winham SJ, Frank RD, Pankratz VS, et al
    Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
    J Clin Oncol. 2018 Apr 20:JCO2017759480. doi: 10.1200/JCO.2017.75.9480.
    PubMed     Text format     Abstract available

  38. DOWSETT M, Sestak I, Regan MM, Dodson A, et al
    Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258.
    PubMed     Text format     Abstract available

  39. WHEELER SB, Spencer JC, Pinheiro LC, Carey LA, et al
    Financial Impact of Breast Cancer in Black Versus White Women.
    J Clin Oncol. 2018 Apr 18:JCO2017776310. doi: 10.1200/JCO.2017.77.6310.
    PubMed     Text format     Abstract available

  40. WANG SY, Dang W, Richman I, Mougalian SS, et al
    Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
    J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941.
    PubMed     Text format     Abstract available

  41. KORNBLUM N, Zhao F, Manola J, Klein P, et al
    Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
    J Clin Oncol. 2018 Apr 17:JCO2017769331. doi: 10.1200/JCO.2017.76.9331.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  42. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Nucl Med

  43. GROHEUX D
    Now is the time to use FDG-PET/CT to optimize neoadjuvant treatment in triple negative breast cancer!
    J Nucl Med. 2018 Apr 19. pii: jnumed.118.210922. doi: 10.2967/jnumed.118.210922.
    PubMed     Text format    


    Oncol Rep

  44. TOPCUL M, Ceti N IL, Ozbas Turan S, Kolusayin Ozar MO, et al
    In vitro cytotoxic effect of PARP inhibitor alone and in combination with nabpaclitaxel on triplenegative and luminal A breast cancer cells.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6364.
    PubMed     Text format     Abstract available


    PLoS One

  45. KORONOWICZ AA, Drozdowska M, Wielgos B, Piasna-Slupecka E, et al
    The effect of "NutramilTM Complex," food for special medical purpose, on breast and prostate carcinoma cells.
    PLoS One. 2018;13:e0192860.
    PubMed     Text format     Abstract available


    Radiology

  46. SEIDENWURM D, Breslau J
    Recall Rate Benchmark for Screening Breast MR Imaging in Community Practice.
    Radiology. 2018;286:728-729.
    PubMed     Text format    

  47. IMBRIACO M, Cuocolo R
    Does Texture Analysis of MR Images of Breast Tumors Help Predict Response to Treatment?
    Radiology. 2018;286:421-423.
    PubMed     Text format    

  48. MOY L
    Do Tumor Shrinkage Patterns at Breast MR Imaging Predict Survival?
    Radiology. 2018;286:58-59.
    PubMed     Text format    

  49. COLIN C
    Mammographic Density: Is There a Public Health Significance Linked to Published Relative Risk Data?
    Radiology. 2017;284:918-919.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: